Michael Engsig
Patrimonio netto: 24 371 $ in data 31/05/2026
Patrimonio netto: 24 371 $ in data 31/05/2026
Michael Thyrring Engsig currently works at Nykode Therapeutics ASA, as Chief Executive Officer from 2019 and FluoGuide A, as Independent Director from 2023.
Mr. Engsig also formerly worked at Takeda A, as Director-Research & Development and KLIFO A, as EVP-Drug Development Counselling.
Mr. Engsig received his graduate degree from Technical University of Denmark.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 10/10/2025 | 71.794 ( 0,02% ) | 24 371 $ | 31/05/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| NYKODE THERAPEUTICS | Amministratore Delegato | 01/01/2019 |
| FLUOGUIDE A/S | Direttore/Membro del Consiglio | 01/01/2023 |
| Società | Posizione | Fine |
|---|---|---|
KLIFO A/S
KLIFO A/S Miscellaneous Commercial ServicesCommercial Services Provides clinical research services | Corporate Officer/Principal | - |
Takeda A/S
Takeda A/S Financial ConglomeratesFinance Engages in holding or owning securities of companies | Direttore Tecnico/Scientifico/R&S | - |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 5 |
|---|---|
Technical University of Denmark
Technical University of Denmark Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
KLIFO A/S
KLIFO A/S Miscellaneous Commercial ServicesCommercial Services Provides clinical research services | Commercial Services |
Takeda A/S
Takeda A/S Financial ConglomeratesFinance Engages in holding or owning securities of companies | Finance |
Nykode Therapeutics ASA
Nykode Therapeutics ASA Pharmaceuticals: MajorHealth Technology Develops vaccines and immunotherapy against infectious diseases and cancer | Health Technology |
FluoGuide A/S
FluoGuide A/S Pharmaceuticals: MajorHealth Technology Engages in the development of drugs used for the improvement of surgical outcomes by making cancer fluorescent | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale